Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology: *1fvgykl*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2NTc2NzcyMC4zMzEuMS4xNjY1NzY3OTU0LjAuMC4w

Dr Sara Saberi (University of Michigan School of Medicine, US) joins us to talk about the findings of the REDWOOD-HCM OLE. This 5-year extension study showed improvement in KCCQ scores in patients with obstructive hypertrophic cardiomyopathy treated with aficamten (Cytokinetics), a novel cardiac myosin inhibitor.

Questions
1. What are some of the unmet needs in patients with hypertrophic cardiomyopathy?
2. Can you please briefly remind us of the findings from the parent study?
3. What was the design of the analysis and what were the baseline characteristics of the patients?
4. What are the key findings?
5. What are the next steps and what are the take-home messages for clinicians?

Recorded remotely from Ann Arbor, 2022.
This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "HFSA 2022: KCCQ Scores In Pts With HCM Treated With Aficamten | Dr Sara Saberi" передвинте ползунок вправо